Parkinson’s disease market across 7MM to grow $7.9 billion in 2033

The market for Parkinson’s disease (PD) drugs across the seven major geographies (7MM; USA, France, Germany, Italy, UK and Japan) is projected to grow at a compound annual growth rate (CAGR) of 8.9% from $3.4 billion in 2023 to $7.9 billion in 2033.

The sector will be driven by the introduction of 10 pipeline products, the increased adoption of novel levodopa delivery methods, and the rising prevalence of PD due to the aging population across the 7MM, according to pharma analytics company GlobalData.

GlobalData’s latest report, “Parkinson’s Disease: Seven-Market Drug Forecast and Market Analysis,” anticipates an increase in sales across most currently marketed PD drug classes. Specifically, levodopa therapies, catechol-o-methyltransferase (COMT) inhibitors, dopamine agonists, monoamine oxidase B (MOA-B) inhibitors, other antiparkinsonian agents, and PD dementia agents.